Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Non-Current Debt (2022 - 2025)

Historic Non-Current Debt for TScan Therapeutics (TCRX) over the last 4 years, with Q3 2025 value amounting to $32.4 million.

  • TScan Therapeutics' Non-Current Debt rose 576.57% to $32.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.4 million, marking a year-over-year increase of 576.57%. This contributed to the annual value of $32.1 million for FY2024, which is 2011.99% up from last year.
  • TScan Therapeutics' Non-Current Debt amounted to $32.4 million in Q3 2025, which was up 576.57% from $32.3 million recorded in Q2 2025.
  • TScan Therapeutics' Non-Current Debt's 5-year high stood at $32.4 million during Q3 2025, with a 5-year trough of $20.1 million in Q2 2024.
  • Over the past 4 years, TScan Therapeutics' median Non-Current Debt value was $29.5 million (recorded in 2023), while the average stood at $28.9 million.
  • Per our database at Business Quant, TScan Therapeutics' Non-Current Debt crashed by 3233.3% in 2024 and then skyrocketed by 6058.07% in 2025.
  • Over the past 4 years, TScan Therapeutics' Non-Current Debt (Quarter) stood at $29.3 million in 2022, then dropped by 8.84% to $26.7 million in 2023, then rose by 20.12% to $32.1 million in 2024, then rose by 1.07% to $32.4 million in 2025.
  • Its last three reported values are $32.4 million in Q3 2025, $32.3 million for Q2 2025, and $32.2 million during Q1 2025.